The High Court decision to disallow patenting of isolated genetic materials is a worry for the innovative medicines sector, says Medicines Australia. “It is essential that Australia maintains strong and stable intellectual property protection that will support the development of new biological medicines,” says Medicines Australia CEO Tim James. “We will need to consider the
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.